- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

S. 297
U.S. Senate•In Senate Committee
Summary
S. 297, the PSA Screening for HIM Act, was introduced in the Senate on Jan 29, 2025 by Sen. John Boozman (R) with 6 co-sponsors. It was referred to Health, Education, Labor, And Pensions, and last saw action on Mar 19, 2026: Committee on Health, Education, Labor, and Pensions. Hearings held.
Record
Text
S. 297 has 6 co-sponsors.
sb297/introduced-in-senate.txt119 S297 IS: Prostate-Specific Antigen Screening for High-risk Insured Men ActU.S. Senate2025-01-29text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.II 119th CONGRESS 1st Session S. 297 IN THE SENATE OF THE UNITED STATES January 29, 2025 Mr. Boozman (for himself and Mr. Booker ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILLTo amend title XXVII of the Public Health Service Act to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings without the imposition of cost-sharing requirements, and for other purposes.1.Short titleThis Act may be cited as the Prostate-Specific Antigen Screening for High-risk Insured Men Act or the PSA Screening for HIM Act .2.FindingsCongress finds the following:(1)Prostate cancer is the second leading cause of cancer death in men in the United States with 1 in 44 men dying from prostate cancer and more than 35,700 men estimated to die from prostate cancer in 2025.(2)Prostate cancer is the second most commonly diagnosed cancer in the Nation with 1 in 8 men being diagnosed in their lifetimes, 3,300,000 men in the United States living with a diagnosis, and over 310,000 men estimated to be diagnosed in 2025.(3)The survival rate for prostate cancer diagnosed in early stage is near 100 percent but prostate cancer diagnosed in late stage has only a 37-percent survival rate.(4)There are few, if any, symptoms of prostate cancer before it reaches late stage.(5)African-American men have a disproportionately higher rate of prostate cancer and are 70 percent more likely to be diagnosed with prostate cancer than White men, with 1 in 6 African-American men developing prostate cancer in their lifetimes.(6)African-American men are 2.1 times more likely to die from prostate cancer than White men.(7)Men with a father or brother with prostate cancer are more than twice as likely to be diagnosed with prostate cancer than men without a family history.(8)The common clinical definition for men at high-risk of prostate cancer includes African-American men and men with a family history.(9)Most of the major cancer and urological societies recommend beginning screening discussions earlier for African-American men and those with a family history of prostate cancer.(10)The United States Preventive Services Task Force has encouraged research on screening African-American men, including whether to screen African-American men at younger ages, and has identified this research as a high-priority cancer research gap.(11)Barriers to screening should be minimized for high-risk men in order to catch asymptomatic prostate cancer before it metastasizes and the survival rate is dramatically reduced.(12)The cost of treating metastatic prostate cancer in the United States health care system is hundreds of millions of dollars more annually than the cost of treating localized, early-stage cancer.3.Requirement for group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings without imposition of cost-sharing requirements(a)In generalSection 2713(a) of the Public Health Service Act ( 42 U.S.C. 300gg–13(a) ) is amended—(1)by striking paragraph (5);(2)by redesignating paragraphs (1) through (4) as subparagraphs (A) through (D), respectively, and adjusting the margins accordingly;(3)by striking (a)In general— A group health and inserting the following:(a)Coverage of preventive health services(1)In generalA group health;(4)in paragraph (1), as so designated—(A)in subparagraph (B), as so redesignated, by striking ; and and inserting a semicolon;(B)in subparagraph (C), as so redesignated, by striking the period and inserting a semicolon;(C)in subparagraph (D), as so redesignated—(i)by striking paragraph (1) and inserting subparagraph (A) ; and(ii)by striking the period and inserting ; and ;(D)by inserting after subparagraph (D), as so redesignated, the following:(E)with respect to men who are age 40 and over and are at high risk of developing prostate cancer (including African-American men and men with a family history of prostate cancer (as defined in paragraph (2))), such additional evidence-based preventive care and screenings not described in subparagraph (A) for prostate cancer.; and(5)by striking the flush text at the end and inserting the following:(2)Men with a family history of prostate cancer definedFor purposes of paragraph (1)(E), the term men with a family history of prostate cancer means men who have a first-degree relative—(A)who was diagnosed with prostate cancer;(B)who developed prostate cancer;(C)whose death was a result of prostate cancer;(D)who have been diagnosed with a cancer known to be associated with increased risk of prostate cancer; or(E)who has a genetic alteration known to be associated with increased risk of prostate cancer.(3)Clarification regarding breast cancer screening, mammography, and prevention recommendationsFor the purposes of this Act, and for the purposes of any other provision of law, the current recommendations of the United States Preventive Service Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current other than those issued in or around November 2009.(4)Rule of constructionNothing in this subsection shall be construed to prohibit a plan or issuer from providing coverage for services in addition to those recommended by the United States Preventive Services Task Force or to deny coverage for services that are not recommended by such Task Force..(b)Effective dateThe amendments made by subsection (a) shall apply with respect to plan years beginning on or after January 1, 2025.
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2025-01-29
- Passed Senate
- Passed House
- Conference
- To President
- Became Law
A bill to amend title XXVII of the Public Health Service Act to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings without the imposition of cost-sharing requirements, and for other purposes.
Sponsors
Sen. John Boozman (R) sponsors S. 297, and 6 members have co-sponsored it, 1 of them from the day it was introduced.

Sen. · R–AR · Sponsor
Introduced Jan 29, 2025

Sen. · D–NJ · Co-sponsor
Joined Jan 29, 2025 · Original

Sen. · D–WA · Co-sponsor
Joined Feb 25, 2025

Sen. · D–CA · Co-sponsor
Joined Feb 25, 2025

Sen. · D–GA · Co-sponsor
Joined Feb 25, 2025

Sen. · D–NH · Co-sponsor
Joined Mar 11, 2025

Sen. · D–DE · Co-sponsor
Joined Mar 12, 2025
Committees
S. 297 went before 1 committee: Health, Education, Labor, and Pensions.

Actions
S. 297 has taken 3 actions since Jan 29, 2025, the latest on Mar 19, 2026.
| Chamber | Action | |||
|---|---|---|---|---|
Mar 19, 2026 | Senate | Committee on Health, Education, Labor, and Pensions. Hearings held.Health, Education, Labor, and Pensions Committee | ||
Jan 29, 2025 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Health, Education, Labor, and Pensions Committee | ||
Jan 29, 2025 | — | Introduced in Senate |
Votes
S. 297 has not gone to a roll call.
Titles
S. 297 goes by 4 titles, 2 of them short titles.
- PSA Screening for HIM Act — Display Title
- PSA Screening for HIM Act — Short Title(s) as Introduced
- Prostate-Specific Antigen Screening for High-risk Insured Men Act — Short Title(s) as Introduced
- A bill to amend title XXVII of the Public Health Service Act to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings without the imposition of cost-sharing requirements, and for other purposes. — Official Title as Introduced
Lobbying
7 clients hired 7 firms and 36 registered lobbyists who named S. 297 in 19 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Budget/Appropriations, Medical/Disease Research/Clinical Labs, Copyright/Patent/Trademark, Defense, Indian/Native American Affairs.
Clients
Who paid to be heard, by how many filings named the bill.
| Client | Business | State | Firms | Filings | Reported |
|---|---|---|---|---|---|
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | — | District of Columbia | 1 | 6 | — |
| ASTELLAS PHARMA US, INC. | — | Illinois | 1 | 6 | — |
| AMERICAN UROLOGICAL ASSOCIATION | Premier urologic association, providing invaluable support to the urologic community | Maryland | 1 | 2 | $60K |
| DENDREON PHARMACEUTICALS LLC | Biopharmaceutical company. | California | 1 | 2 | $60K |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | — | District of Columbia | 1 | 1 | — |
| NATIONAL ASSOCIATION OF NUCLEAR PHARMACIES | Non-profit industry association of over four hundred nuclear pharmacies | District of Columbia | 1 | 1 | — |
| VANDERBILT UNIVERSITY MEDICAL CENTER | — | Tennessee | 1 | 1 | — |
Firms
Registrants who filed on the bill, by filings.
| Registrant | Clients | Filings | Reported |
|---|---|---|---|
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 1 | 6 | — |
| ASTELLAS PHARMA US, INC. | 1 | 6 | — |
| THE MCMANUS GROUP | 1 | 2 | $60K |
| VENABLE LLP | 1 | 2 | $60K |
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 1 | 1 | — |
| BOSE PUBLIC AFFAIRS GROUP | 1 | 1 | — |
| VANDERBILT UNIVERSITY MEDICAL CENTER | 1 | 1 | — |
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 36.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| AKSHAI DATTA | 1 | 1 | 6 |
| ELIZABETH DARNALL | 1 | 1 | 6 |
| JAMES WILLIAMS | 1 | 1 | 6 |
| JONATHAN OEHMEN | 1 | 1 | 6 |
| JULIE NICKSON | 1 | 1 | 6 |
| MARC GOTTSCHALK | 1 | 1 | 6 |
| NISHITH PANDYA | 1 | 1 | 6 |
| ALEXANDER SUTTON | 1 | 1 | 5 |
| ANGELA SAILOR | 1 | 1 | 4 |
| ERIKA NINOYU | 1 | 1 | 4 |
| DEEPTI LOHARIKAR | 1 | 1 | 2 |
| JELANI MURRAIN | 1 | 1 | 2 |
| JIM TWADDELL | 1 | 1 | 2 |
| JOHN MCMANUS | 1 | 1 | 2 |
| JOHN V. DRZEWICKI | 1 | 1 | 2 |
| LAURA HANEN | 1 | 1 | 2 |
| ADAM BECK | 1 | 1 | 1 |
| ALEXANDER CURRIE | 1 | 1 | 1 |
| ANDREW SHINE | 1 | 1 | 1 |
| ANNA DUNBAR-HESTER | 1 | 1 | 1 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2025 first_quarter | $4.8M | 1st Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2025 second_quarter | $2.6M | 2nd Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2025 fourth_quarter | $2.4M | 4th Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2026 first_quarter | $2.3M | 1st Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2025 third_quarter | $2.1M | 3rd Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2025 first_quarter | $2M | 1st Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2026 second_quarter | $1.2M | 2nd Quarter - Report |
| ASTELLAS PHARMA US, INC. | ASTELLAS PHARMA US, INC. | 2025 fourth_quarter | $980K | 4th Quarter - Report |
| ASTELLAS PHARMA US, INC. | ASTELLAS PHARMA US, INC. | 2025 third_quarter | $850K | 3rd Quarter - Report |
| ASTELLAS PHARMA US, INC. | ASTELLAS PHARMA US, INC. | 2025 second_quarter | $670K | 2nd Quarter - Report |
| ASTELLAS PHARMA US, INC. | ASTELLAS PHARMA US, INC. | 2026 first_quarter | $590K | 1st Quarter - Report |
| ASTELLAS PHARMA US, INC. | ASTELLAS PHARMA US, INC. | 2025 first_quarter | $560K | 1st Quarter - Report |
| ASTELLAS PHARMA US, INC. | ASTELLAS PHARMA US, INC. | 2026 second_quarter | $510K | 2nd Quarter - Report |
| VANDERBILT UNIVERSITY MEDICAL CENTER | VANDERBILT UNIVERSITY MEDICAL CENTER | 2025 fourth_quarter | $50K | 4th Quarter - Report |
| AMERICAN UROLOGICAL ASSOCIATION | VENABLE LLP | 2025 fourth_quarter | $30K | 4th Quarter - Termina… |
| AMERICAN UROLOGICAL ASSOCIATION | VENABLE LLP | 2025 third_quarter | $30K | 3rd Quarter - Report |
| DENDREON PHARMACEUTICALS LLC | THE MCMANUS GROUP | 2025 second_quarter | $30K | 2nd Quarter - Report |
| DENDREON PHARMACEUTICALS LLC | THE MCMANUS GROUP | 2025 first_quarter | $30K | 1st Quarter - Report |
| NATIONAL ASSOCIATION OF NUCLEAR PHARMACIES | BOSE PUBLIC AFFAIRS GROUP | 2025 third_quarter | — | 3rd Quarter - Report |
Classification
The Congressional Research Service files S. 297 under Health, one of its 31 policy areas, and gives it 5 legislative subjects.
CRS Subjects
CRS assigns every bill one policy area from its 31; S. 297’s is Health.
s297/policy-areas.txtLegislative Subjects
S. 297 carries 5 of CRS’s legislative subjects, from Cancer to Medical tests and diagnostic methods.
s297/subjects.txtSource: congress.gov · legiscan.com